Regeneron Pharmaceuticals (REGN) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for Regeneron Pharmaceuticals, as the data feed reports them.

Analysts' mean target, 27 analysts
$990.81
3.5% above the price

The 27 analysts reported by the data feed have a mean price target for Regeneron Pharmaceuticals of $990.81, 3.5% above the $957.76 price (range $812.00–$1,175.00). 2.27% of the float was sold short as of Oct 30, 2026. Institutions hold 92.2% of the shares and insiders 2.1%. Source: Yahoo Finance, read Nov 18, 2026.

Key facts

Analysts' mean target
$990.81+3.5% vs price
Analysts
27
Short interest
2.27%of float, Oct 30, 2026
Short ratio
2.93 days
Institutions
92.2%
Insiders
2.15%
Beta
0.1
Next earnings
Jan 28, 2027estimated

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

27 analysts covering Regeneron Pharmaceuticals, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $957.76.

Analysts' price targets for Regeneron Pharmaceuticals
Mean price target$990.813.5% above the price (+3.5%)
Median price target$1,000.004.4% above the price (+4.4%)
Highest target$1,175.0022.7% above the price (+22.7%)
Lowest target$812.0015.2% below the price (−15.2%)
Analysts with a target27

Ratings this month · 28 analysts

Strong buy 4(14%)Buy 15(54%)Hold 9(32%)
Analysts' ratings of Regeneron Pharmaceuticals this month, by rating
RatingAnalystsShare
Strong buy414%
Buy1554%
Hold932%
Sell00%
Strong sell00%

The feed averages these to 1.79 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “buy”.

Who owns Regeneron Pharmaceuticals

Ownership of Regeneron Pharmaceuticals
Held by institutions92.2%2,044 institutions; percent of shares outstanding
Held by institutions, of the float94.2%
Held by insiders2.15%percent of shares outstanding
Shares outstanding101.63M
Float96.35Mshares available to trade
Insiders' net purchases, six months+22.86K13 purchases (71.33K shares), 12 sales (48.47K shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in Regeneron Pharmaceuticals
Shares short2.22Mas of Oct 30, 2026
Percent of float2.27%shares short ÷ float
Percent of shares outstanding2.14%shares short ÷ shares outstanding
Short ratio (days to cover)2.93shares short ÷ average daily volume

Regeneron Pharmaceuticals short interest from FINRA, with its history

Trading figures

Trading figures for Regeneron Pharmaceuticals
Beta0.1movement against the market; 1 moves with it
52-week high$991.73
52-week low$591.52
Average volume, 3 months800.35Kshares a day
Average volume, 10 days1.08Mshares a day

Dates to know

Upcoming and recent dates for Regeneron Pharmaceuticals
Next earnings reportJan 28, 2027the feed's estimate, not confirmed
Ex-dividend dateNov 20, 2026as the feed lists it
Dividend payment dateDec 3, 2026

Questions and answers

What is the analysts' price target for Regeneron Pharmaceuticals (REGN)?

As reported by the data feed, the mean price target of the 27 analysts covering Regeneron Pharmaceuticals is $990.81, 3.5% above the latest price of $957.76. The highest target is $1,175.00 and the lowest $812.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate Regeneron Pharmaceuticals stock?

Of the 28 ratings the data feed reports for the current month, 4 are strong buy, 15 buy, 9 hold, 0 sell and 0 strong sell.

How many Regeneron Pharmaceuticals shares are sold short?

As reported by the data feed, 2.22M shares were sold short, 2.27% of the float as of Oct 30, 2026. At the average daily volume that is 2.93 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns Regeneron Pharmaceuticals stock?

As reported by the data feed, institutions hold 92.2% of the shares (2,044 institutions) and insiders 2.1%. There are 101.63M shares outstanding, of which 96.35M are in the float.

When is Regeneron Pharmaceuticals's next earnings report?

The data feed lists Jan 28, 2027, marked as its estimate rather than a date the company has confirmed. The latest ex-dividend date it lists is Nov 20, 2026.

How much does Regeneron Pharmaceuticals stock move with the market?

Its beta, as reported by the data feed, is 0.1: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $591.52 and $991.73.

Cite this page

Funkfolio, “Regeneron Pharmaceuticals (REGN) statistics and analyst targets”, data as of 18 November 2026. https://funkfolio.com/stock/REGN/statistics

Underlying data: Yahoo Finance.